Janus Henderson Group PLC Vaxart, Inc. Transaction History

Janus Henderson Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.09 - $4.5 $104 - $225	50 Added 0.21%	23,972 $52,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $5.28 $62 - $121	-23 Reduced 0.1%	23,922 $84,000
Q1 2022 May 16, 2022	BUY	$4.29 - $6.64 $25 - $39	6 Added 0.03%	23,945 $121,000
Q4 2021 Feb 14, 2022	BUY	$5.77 - $7.96 $69,522 - $95,910	12,049 Added 101.34%	23,939 $150,000
Q3 2021 Nov 16, 2021	BUY	$6.67 - $9.8 $79,306 - $116,522	11,890 New	11,890 $95,000

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.